Insider Trades
Common-stock transactions that officers, directors and 10% owners of healthcare companies report to the SEC on Form 4, from 2006 to today, newest first.
Insider filings are public records and are not a recommendation.
Results
25+ transactions, newest first
| Date | Insider | Relationship | Company | Transaction | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Bernstein Bruce | Director | Petros Pharmaceuticals, Inc.PTPI | OtherA · Grant or award from the company | 1,875,000 | $0.00 | $0 | 3,762,334Direct | Form 4 filed 5 Jun 2026, on sec.gov (opens in a new tab)Filed 5 Jun 2026 | |
| Boctor Fady | See Remarks | Petros Pharmaceuticals, Inc.PTPI | OtherA · Grant or award from the company | 375,000 | $0.00 | $0 | 894,986Direct | Form 4 filed 5 Jun 2026, on sec.gov (opens in a new tab)Filed 5 Jun 2026 | |
| Silverman Joshua | Director | Petros Pharmaceuticals, Inc.PTPI | OtherA · Grant or award from the company | 4,375,000 | $0.00 | $0 | 8,790,450Direct | Form 4 filed 5 Jun 2026, on sec.gov (opens in a new tab)Filed 5 Jun 2026 | |
| WALKER WAYNE REMELL | Director | Petros Pharmaceuticals, Inc.PTPI | OtherA · Grant or award from the company | 375,000 | $0.00 | $0 | 881,333Direct | Form 4 filed 8 Jun 2026, on sec.gov (opens in a new tab)Filed 8 Jun 2026 | |
| Silverman Joshua | Director | Petros Pharmaceuticals, Inc.PTPI | OtherA · Grant or award from the company | 4,375,000 | $0.00 | $0 | 4,415,450Direct | Form 4 filed 2 Jan 2026, on sec.gov (opens in a new tab)Filed 2 Jan 2026 | |
| WALKER WAYNE REMELL | Director | Petros Pharmaceuticals, Inc.PTPI | OtherA · Grant or award from the company | 500,000 | $0.00 | $0 | 506,333Direct | Form 4 filed 2 Jan 2026, on sec.gov (opens in a new tab)Filed 2 Jan 2026 | |
| Bernstein Bruce | Director | Petros Pharmaceuticals, Inc.PTPI | OtherA · Grant or award from the company | 1,875,000 | $0.00 | $0 | 1,887,334Direct | Form 4 filed 2 Jan 2026, on sec.gov (opens in a new tab)Filed 2 Jan 2026 | |
| Boctor Fady | See Remarks | Petros Pharmaceuticals, Inc.PTPI | OtherA · Grant or award from the company | 500,000 | $0.00 | $0 | 519,986Direct | Form 4 filed 6 Jan 2026, on sec.gov (opens in a new tab)Filed 6 Jan 2026 | |
| Arnold Mitchell | See Remarks | Petros Pharmaceuticals, Inc.PTPI | OtherA · Grant or award from the company | 150,000 | $0.00 | $0 | 150,000Direct | Form 4 filed 21 Feb 2025, on sec.gov (opens in a new tab)Filed 21 Feb 2025 | |
| Boctor Fady | See Remarks | Petros Pharmaceuticals, Inc.PTPI | OtherA · Grant or award from the company | 450,000 | $0.00 | $0 | 499,645Direct | Form 4 filed 21 Feb 2025, on sec.gov (opens in a new tab)Filed 21 Feb 2025 | |
| WALKER WAYNE REMELL | Director | Petros Pharmaceuticals, Inc.PTPI | OtherA · Grant or award from the company | 150,000 | $0.00 | $0 | 158,314Direct | Form 4 filed 21 Feb 2025, on sec.gov (opens in a new tab)Filed 21 Feb 2025 | |
| Silverman Joshua | Director | Petros Pharmaceuticals, Inc.PTPI | OtherA · Grant or award from the company | 1,000,000 | $0.00 | $0 | 1,011,237Direct | Form 4 filed 21 Feb 2025, on sec.gov (opens in a new tab)Filed 21 Feb 2025 | |
| Bernstein Bruce | Director | Petros Pharmaceuticals, Inc.PTPI | OtherA · Grant or award from the company | 300,000 | $0.00 | $0 | 308,346Direct | Form 4 filed 21 Feb 2025, on sec.gov (opens in a new tab)Filed 21 Feb 2025 | |
| Boctor Fady | See Remarks | Petros Pharmaceuticals, Inc.PTPI | OtherA · Grant or award from the company | 49,645 | $0.00 | $0 | 49,645Direct | Form 4 filed 26 Dec 2023, on sec.gov (opens in a new tab)Filed 26 Dec 2023 | |
| Bernstein Bruce | Director | Petros Pharmaceuticals, Inc.PTPI | OtherM · Option or derivative exercised or converted | 6,050 | Not reported | No price reported | 8,346Direct | Form 4 filed 28 Apr 2023, on sec.gov (opens in a new tab)Filed 28 Apr 2023 | |
| WALKER WAYNE REMELL | Director | Petros Pharmaceuticals, Inc.PTPI | OtherM · Option or derivative exercised or converted | 6,050 | Not reported | No price reported | 8,314Direct | Form 4 filed 28 Apr 2023, on sec.gov (opens in a new tab)Filed 28 Apr 2023 | |
| Silverman Joshua | Director | Petros Pharmaceuticals, Inc.PTPI | OtherM · Option or derivative exercised or converted | 6,722 | Not reported | No price reported | 11,237Direct | Form 4 filed 28 Apr 2023, on sec.gov (opens in a new tab)Filed 28 Apr 2023 | |
| Bradley Greg | Director | Petros Pharmaceuticals, Inc.PTPI | OtherM · Option or derivative exercised or converted | 6,050 | Not reported | No price reported | 8,314Direct | Form 4 filed 28 Apr 2023, on sec.gov (opens in a new tab)Filed 28 Apr 2023 | |
| WALKER WAYNE REMELL | Director | Petros Pharmaceuticals, Inc.PTPI | OtherM · Option or derivative exercised or converted | 2,264 | Not reported | No price reported | 2,264Direct | Form 4 filed 25 Jan 2023, on sec.gov (opens in a new tab)Filed 25 Jan 2023 | |
| Bernstein Bruce | Director | Petros Pharmaceuticals, Inc.PTPI | OtherM · Option or derivative exercised or converted | 2,264 | Not reported | No price reported | 2,296Direct | Form 4 filed 25 Jan 2023, on sec.gov (opens in a new tab)Filed 25 Jan 2023 | |
| Silverman Joshua | Director | Petros Pharmaceuticals, Inc.PTPI | OtherM · Option or derivative exercised or converted | 2,515 | Not reported | No price reported | 4,515Direct | Form 4 filed 25 Jan 2023, on sec.gov (opens in a new tab)Filed 25 Jan 2023 | |
| Bradley Greg | Director | Petros Pharmaceuticals, Inc.PTPI | OtherM · Option or derivative exercised or converted | 2,264 | Not reported | No price reported | 2,264Direct | Form 4 filed 25 Jan 2023, on sec.gov (opens in a new tab)Filed 25 Jan 2023 | |
| Juggernaut Partners III GP, L.P.; JCP III SM AIV, L.P.; METP Holdings LLC; SHULMAN JOHN D; Juggernaut Partners III GP, Ltd. | Director, 10% owner | Petros Pharmaceuticals, Inc.PTPI | BuyP · Open-market or private purchase | 145,773 | $3.43 | $500,001.39 | 5,703,544Indirect, See Footnote | Form 4 filed 3 Jan 2022, on sec.gov (opens in a new tab)Filed 3 Jan 2022 | |
| Juggernaut Partners III GP, Ltd.; SHULMAN JOHN D; Juggernaut Partners III GP, L.P.; METP Holdings LLC; JCP III SM AIV, L.P. | Director, 10% owner | Petros Pharmaceuticals, Inc.PTPI | BuyP · Open-market or private purchase | 500,000 | $3.00 | $1,500,000 | 5,557,771Indirect, See Footnote | Form 4 filed 30 Nov 2021, on sec.gov (opens in a new tab)Filed 30 Nov 2021 | |
| SHULMAN JOHN D; METP Holdings LLC; JCP III SM AIV, L.P.; Juggernaut Partners III GP, L.P.; Juggernaut Partners III GP, Ltd. | Director, 10% owner | Petros Pharmaceuticals, Inc.PTPI | BuyP · Open-market or private purchase | 1,661,807 | $1.72 | $2,858,308.04 | 5,057,771Indirect, See Footnote | Form 4 filed 21 Oct 2021, on sec.gov (opens in a new tab)Filed 21 Oct 2021 |
Source: SEC EDGAR Form 4 filings and the SEC Insider Transactions Data Sets (2006 onward). Each row links to its Form 4 filing. Values are shares times the reported price. Nothing here is investment advice.